Antibiotic therapies are widely used for treating infectious diseases (
1). Nowadays, antibiotic-resistant bacteria are a great concern of worldwide public health (
2). The nosocomial infections, caused by multidrug-resistant (MDR) bacteria, are one of the most important causes of mortality throughout the world (
3). Therefore, multi-drug-resistant Gram-negative rods will be a serious problem if no adequate action is taken (
4,
5). Unfortunately, the issue of antibiotic resistant bacteria in Iran is increasing, following the rising trend of its global counterpart (
6). One of the most common reasons for this trend is represented by the widespread overuse and incorrect prescribing practices. Resistant bacteria possess resistance gene cassettes, which protect antibiotic-producing bacteria against these biological active molecules (
7-
9). The most important resistance mechanism against beta-lactam antibiotics is producing beta-lactamases, especially by Gram-negative bacteria (
10,
11). The β-lactamases are classified into four molecular classes, according to Bush-Jacoby classification system (
12). During the last years, the distribution of carbapenemase-producing
Enterobacteriaceae has emerged almost globally. There is no general protocol for treating severe infections that are caused by carbapenemase-producing bacteria. Fosfomycin, tigecycline and polymyxins such as polymyxin B or colistin are offered for these cases. In serious circumstances, combination therapy is recommended, rather than monotherapy. Several newly discovered antibiotics have been approved to aid treatment options. Avibactam, as a non-beta-lactam beta-lactamase inhibitor, acts against OXA-48 carbapenemases and almost all A and B beta-lactamase classes (including strains expressing class A carbapenemases and/or derepressed AmpC enzymes). Ceftazidime or aztreonam, in combination with avibactam, are also effective (
13,
14).
Enterobacteriaceae and non-fermentative bacteria, like
Pseudomonas aeruginosa (
P. aerugionsa) and
Acinetobacter baumannnii (
A. baumanii) are able of producing carbapenemases. The classification of these enzymes is as follows: group A (KPC, SME, IMI and NMC), group B (VIM, IMP, SPM, GIM, NDM, SIM, DIM and AIM) and group D (OXA-23, OXA-24, OXA-48, OXA-58 and OXA-143). Since the 1990s, metallo-β-lactamase (MBL) producing bacteria have been reported from many regions of the world (
12,
15). An important percentage of Gram-negative pathogenic bacteria are resistant to β-lactam antibiotics, through MBLs production. Verona integron-encoded MBLs (VIM) (
12,
16) and imipenemase (IMP) (
12) are the main MBLs family members.